Mankind Pharma Q2 Profit Rises Nearly 38% on Revenue Growth and Domestic Demand
Mankind Pharma reported a 37.7-39.2% year-on-year rise in net profit to around Rs 712-716 crore for Q2 FY27, supported by a 17.3% increase in revenue to Rs 4,338 crore. The company saw strong domestic growth, particularly in chronic therapies, and a 33% rise in international revenue. EBITDA margins improved by about 210 basis points. The firm also highlighted its recent acquisition of Armed Cell Therapeutics, marking entry into next-generation CAR-T therapies. Shares rose 3.4-4.5% following the results.
First-hand measurement across 2 sources
We measured how 2 outlets covered this story. No outlet gave this story a measurable political slant — there is no left–right reading to report. Overall sentiment is positive (75/100). Lens Score 36/100.
Outlets measured: freepressjournal, moneycontrol. See how each one headlined and framed the same story in the source comparison below.
AI Analysis
Sentiment was consistent across outlets (74–75/100), indicating broadly factual reporting rather than editorialising.
Coverage timeline
moneycontrol broke this story on 26 Oct, 10:01 am. Other outlets followed.